Indium (111In) Biciromab

N/A

Report date: 2025/09/08 14:40:41

Base Information

Drug NameIndium (111In) Biciromab

Drug Alias NameBiciromab111In-BiciromabFibriScintT2G1s

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody murineBiologics > Protein drugs > Immunoglobulin > Antibody > Antibody conjugate > Antibody diagnosticsRadiation-emitting products > Radioactive therapeutic agent +[5]

Mechanisms of ActionFibrinogen beta chain inhibitors

TargetsFibrinogen beta chain

Therapy Area/IndicationsDiagnostic agentsThromboembolism

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryN/A

CombinationsNo

Global Highest StatusWithdrawn

Highest Status in ChinaN/A

Originator CompaniesJohnson & Johnson Innovative Medicine

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesJohnson & Johnson Innovative Medicine

Active IndicationsN/A

Inactive IndicationsDiagnostic agentsThromboembolism

Other Information

ATC CodeL01XC